Smokeless Tobacco Product Warning Statements: Request for Comments and Scientific Evidence
This Notice document was issued by the Food and Drug Administration (FDA)
For related information, Open Docket Folder
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 1142
[Docket No. FDA-2012-N-1032]
Smokeless Tobacco Product Warning Statements; Request for Comments and Scientific Evidence
Food and Drug Administration, HHS.
Notification; request for comments.
The Food and Drug Administration (FDA) is establishing a public docket to obtain comments, supported by scientific evidence, regarding what changes to the smokeless tobacco product warnings, if any, would promote greater public understanding of the risks associated with the use of smokeless tobacco products.
Submit electronic or written comments by April 1, 2013.
Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document.
For Further Information Contact
Gail Schmerfeld,Center for Tobacco Products,9200 Corporate Blvd.,Rockville, MD 20850-3229,1-877-287-1373, email@example.com.
On June 22, 2009, the President signed the Family Smoking Prevention and Tobacco Control Act (Pub. L. 111-31) (Tobacco Control Act) into law. The Tobacco Control Act grants FDA authority to regulate the manufacture, marketing, and distribution of tobacco products to protect public health generally and to reduce tobacco use by minors.
Section 204 of the Tobacco Control Act amended section 3 of the Comprehensive Smokeless Tobacco Health Education Act (Smokeless Tobacco Act) (15 U.S.C. 4402) to prescribe new requirements for health warnings that must appear on smokeless tobacco product packages and advertising. The Smokeless Tobacco Act (15 U.S.C. 4402(a)(1) and (b)(1)), requires that smokeless tobacco product packages and advertising must bear one of four required warning statements. The four required warning statements are:
“WARNING: This product can cause mouth cancer.”
“WARNING: This product can cause gum disease and tooth loss.”
“WARNING: This product is not a safe alternative to cigarettes.”
“WARNING: Smokeless tobacco is addictive.” (15 U.S.C. 4402(a)(1))
One of the four required warning statements must be located on each of the two principal display panels of the package and comprise at least 30 percent of each such display panel (15 U.S.C. 4402(a)(2)(A)). The Smokeless Tobacco Act (15 U.S.C. 4402(a)(2) and (b)(2)), also sets forth requirements for the placement, type, size, and color of warnings on packaging and advertisements, respectively.
Section 205(a) of the Tobacco Control Act further amended section 3 of the Smokeless Tobacco Act to give FDA the authority to “adjust the format, type size and text of any of the label requirements, require color graphics to accompany the text, increase the required label area from 30 up to 50 percent of the front and rear panels of the package, or establish the format, type size, and text of any other disclosures required under the Federal Food, Drug, and Cosmetic Act” through rulemaking conducted under the Administrative Procedures Act (5 U.S.C. 552, et seq.) if FDA “finds that such a change would promote greater public understanding of the risks associated with the use of smokeless tobacco products” (15 U.S.C. 4402(d)).
II. Request for Scientific Evidence and Information
We are interested in comments, supported by scientific evidence, regarding what changes, if any, to the smokeless tobacco product warnings would promote greater public understanding of the risks associated with the use of smokeless tobacco products. The “public” includes both tobacco users and nonusers (i.e., never users and former users). Comments and supporting evidence should address how any changes in the warnings would affect both users' and nonusers' understanding of the risks associated with the use of smokeless tobacco products.
Interested persons may submit either written comments regarding this document to the Division of Dockets Management (seeADDRESSES) or electronic comments to http://www.regulations.gov. It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.
Dated: January 18, 2013.
Assistant Commissioner for Policy.
[FR Doc. 2013-01626 Filed 1-28-13; 8:45 am]
BILLING CODE 4160-01-P
No documents available.
| || |
Comment Period Closed
Apr 1 2013, at 11:59 PM ET
Show More Details
Date Posted: Jan 29, 2013
CFR: 21 CFR Part 1142
Federal Register Number: 2013-01626
At Respiratory Health Association, we are dedicated to improving lung health and recognize that graphic warning labels are an effective method of reducing...
See attached file(s)
See attached comments.
This document is contained in
Related RINs: None
* This count refers to the total comment/submissions received on this document, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.
Document text and images courtesy of the